MSMiriam Sánchez-Escamilla

Miriam Sánchez-Escamilla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miriam Sánchez-Escamilla has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Incidence, clinical risk factors, and biomarkers of SOS/VOD following allogeneic HSCT in adults. A real-life study by the Spanish group of HSCT and cell therapy (GETH-TC).

    by Ariadna Pérez-Martínez, Mónica Cabrero, Juan Montoro, Miriam Sánchez-Escamilla, María Ángeles Cuesta, Valle Gómez-García de Soria, Pedro González-Sierra, Karem Humala, Oriana López-Godino, Alejandro Luna de Abia, et al.

    Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) may occur after allo-HSCT. This retrospective study of 793 allo-HSCT performed in adult patients analyzes the impact of clinical risk factors and the EASIX score on the incidence and outcomes of SOS/VOD using Real-World data (GETH-TC registry). Severity and clinical risk factors were defined according to the EBMT-2023 criteria. The EASIX score was calculated at three time points after allo-HSCT (EASIX-day 0, d + 7, d + 14). SOS/VOD developed in 79 patients (10%), at a median time of 15 days. The cumulative incidence of SOS/VOD at 30 and 90 days post-HSCT was 8.58% and 9.97%, respectively. Defibrotide was used in 44 patients (56%) who developed SOS/VOD. Patients with SOS/VOD experienced an increased risk of NRM (HR 5.56; p < 0.001). Multivariate analysis confirmed the prognostic value for SOS/VOD incidence of second or subsequent HSCT, use of parenteral nutrition, high tacrolimus/sirolimus levels, INR > 1.5 before SOS, as well as day 0 EASIX ≥ 2 (sHR 1.67; p = 0.036), d + 7 EASIX ≥ 6 (sHR 2.86; p < 0.001), and d + 14 EASIX ≥ 6 (sHR 2.87; p = 0.003). In conclusion, SOS/VOD incidence is similar to previous series and significantly impacts NRM. EASIX score was validated as a risk factor of SOS/VOD.

  • FEASIBILITY AND INTERIM SAFETY AND EFFICACY ANALYSIS OF A FAST AUTOMATED PRODUCTION OF PROPHYLACTIC CMV-SPECIFIC CTLs AFTER ALLOGENEIC HSCT

    by Ma Aránzazu Bermúdez, Oscar M. Pello, Miriam Sánchez-Escamilla, Sara Vallejo-Díez, Marta Fernández-Martínez, Lucía Lavín-Alconero, Mercedes Colorado, Iñigo Romón, Gala A. Méndez-Navarro, Patricia Vega, et al.


  • Factors associated with long-term quality of life after allogenic stem cell transplantation

    by Juan J. Domínguez-García, Miriam Sánchez Escamilla, Sara García-Ávila, Brenda López Pereira, Guillermo Martín Sánchez, Miguel Á. Cortés Vázquez, José A. Calvo Sánchez, Sergio Fernández García, Leddy P. Vega Suárez, Enrique M. Ocio San Miguel, et al.

    Allo-HSCT is a potentially curative treatment for hematologic diseases, but long-term quality of life (QoL) remains a concern. Factors like GVHD, comorbidities, and post-transplant complications can impact survivorship. Understanding QoL in long-term survivors is key to improving care strategies. This observational study included allo-HSCT patients aged ≥18 years, transplanted between January 2010 and December 2015. QoL was assessed by telephone using FACT-BMT and EQ-5D-5L, along with clinical data. Statistical analyses examined associations between QoL and clinical factors. Sixty-seven long-term survivors participated (median follow-up: 7 years). The mean FACT-BMT score was 115.2/148, indicating generally good QoL. However, patients with active GVHD showed reduced physical and emotional functioning. Stem cell source also influenced specific FACT-BMT subscores. Long-term QoL after allo-HSCT is generally favorable, but physical and emotional challenges persist, especially with active GVHD. Targeted interventions and proactive management are crucial to improving overall survivorship care.


  • Open Access

    Fixed Low-Dose ATLG in HLA-Matched Transplantation is Safe and Effective

    by J.M. Cerezo-Martin, L. Yañez San-Segundo, J. Bannatyne, S. Fernández-Luis, M. Sánchez-Escamilla, M.M. Colorado-Araujo, G. Martin-Sánchez, N. Fernández-Escalada, I. Romón, E.M. Ocio, et al.

  • Open Access

    Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells

    by Martina Pennisi, Miriam Sanchez-Escamilla, Jessica Flynn, Molly A. Maloy, Mari Lynne Silverberg, Yakup Batlevi, Roni Shouval, Connie Lee Batlevi, Renier J. Brentjens, Sean M. Devlin, et al.

    Introduction Chimeric Antigen Receptor (CAR) T cells are associated with unique toxicities, including cytokine release syndrome (CRS) and immune effector cells-associated neurotoxicity syndrome (ICANS). Patients (pts) with severe CRS and ICANS exhibit hemodynamic instability and coagulopathy with evidence of endothelial activation and increased blood brain barrier permeability. Increases in inflammatory cytokines and biomarkers of endothelial activation in serum and CSF have been associated with severe CRS and ICANS. The EASIX (Endothelial Activation and Stress Index) score [lactate dehydrogenase (LDH) (U/L) × creatinine (mg/dl) / platelets (PLT) (109 cells/L)] correlates with severe fluid overload and survival in allogeneic transplant pts. Elevated LDH and low PLT levels have been associated with severe ICANS development, and high IL-6 levels are seen in severe CRS and ICANS. We hypothesized that the EASIX and a newly proposed version of it, the modified-EASIX (mEASIX), in which creatinine is replaced by CRP (mg/dL) as an easily available surrogate for IL6, would be associated with CRS and ICANS in CAR T cells pts. Methods We analyzed 2 different populations of adult CAR T cells pts treated at our institution: 1) B-cell acute lymphoblastic leukemia (B-ALL) pts treated with CD1928z CAR T cells from 2010 to 2016 (NCT01044069), and 2) aggressive diffuse large B-cell lymphoma (DLBCL) pts treated with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) after FDA approval starting from 2018. EASIX and mEASIX scores were calculated for each patient daily from start of lymphodepletion conditioning to day +14. A log transformation using base 2 (log2) was applied to all EASIX/mEASIX variables to reduce skew. CRS and ICANS were graded according to the ASTCT grading system. Results 87 pts, B-ALL (n=53) and DLBCL (n=34), were analyzed. According to ASTCT grading, 83% (72/87) experienced CRS and 54% (47/87) developed ICANS, grade ≥3 in 23% (20/87) and 40% (35/87) of pts, respectively. When analyzed by disease, CRS and ICANS rates were 87% (46/53) and 55% (29/53) for B-ALL and 76% (26/34) and 53% (18/34) for DLBCL, respectively. CRS and ICANS were grade ≥3 in 28% (15/53) and 45% (24/53) of B-ALL pts and in 15% (5/34) and 32% (11/34) of DLBCL pts, respectively. Median time of onset of CRS after CAR T cell infusion was day +2 and median onset of ICANS was day +6 for the overall population and the subgroups. High EASIX and mEASIX scores at start of conditioning were both associated with development of any grade CRS [OR=1.81 (95% CI 1.09-3.36) p=0.038 and OR=1.94 (95% CI 1.32-3.38) p=0.005] and grade ≥3 CRS [OR=1.47 (95% CI 1.05-2.29) p=0.049 and OR=1.34 (95% CI 1.07-1.80) p=0.024], respectively (Table). Following CAR T cell infusion, high scores of both EASIX [OR=1.60 (95% CI 1.12-2.43) p=0.017] and mEASIX [OR=1.32 (95% CI 1.07-1.69) p=0.014] on day +1 were associated with development of grade ≥3 CRS. Moreover, both high EASIX [OR=1.43 (95% CI 1.08-1.96) p=0.018] and mEASIX [OR=1.29 (95% CI 1.07-1.60) p=0.010] scores on day +3 were associated with grade ≥3 ICANS. When analyzed by disease, results were confirmed for severe CRS and ICANS in B-ALL patients, while in the DLBCL group only mEASIX at start of conditioning and at day +1 was associated with development of any grade CRS. EASIX and mEASIX scores were not associated with response rates to CAR T cells therapy. Conclusions EASIX and mEASIX scores calculated at baseline (before lymphodepletion) are associated with development of CRS and severe CRS. Moreover, both high EASIX and mEASIX scores on day +1 and day +3 are associated with occurrence of grade ≥3 CRS and grade ≥3 ICANS, respectively. We conclude that EASIX and mEASIX, as markers of endothelial damage and inflammation, could be useful as early predictors in guiding treatment decisions before the onset of severe symptoms.